Use of antisense vectors and oligodeoxynucleotides in neuro-oncology

Pediatric Neurosurgery

Volumn 28, Issue 6, 1998, Pages 279-285

  Engelhard, Herbert H ^a,b   Egli, Martin ^a   Rozental, Jack M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Neurological Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; COMPLEMENTARY DNA; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; PHOSPHOROTHIOIC ACID; PROTEIN KINASE C;

ANIMAL MODEL; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DRUG HALF LIFE; GENE TARGETING; GENE THERAPY; GROWTH INHIBITION; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS; DNA, ANTISENSE; GENETIC VECTORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, NUDE;

EID: 0031694240     PISSN: 10162291     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028665     Document Type: Review

References (100)

1. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-284.
2. Stephenson ML, Zamecnik PC: Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:285-288.
3. Agrawal S: Antisense oligonucleotides: Towards clinical trials. Trends Biotechnol 1996;14:376-387.
4. Brysch W, Schlingensiepen K-H: Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents. Cell Mol Neurobiol 1994;14:557-568.
5. Crooke ST, Bennett CF: Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 1996;36:107-129.
6. Ho PTC, Parkinson DR: Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997;24:187-202.
7. Szymkowski DE: Developing antisense oligonucleotides from the laboratory to clinical trials. Drug Discovery Today 1996;1:415-428.
8. Weintraub HM: Antisense RNA and DNA. Sci Am 1990;262:34-40.
9. Engelhard HH: Antisense oligonucleotide technology: Potential use for the treatment of malignant brain tumors. Cancer Control 1998;5:163-170.
10. Hall WA, Flores EP, Low WC Antisense oligonucleotides for central nervous system tumors. Neurosurgery 1996;38:376-382.
11. Altmann K-H, Fabbro D, Dean NM, et al.: Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem Soc Trans 1996;24:630-637.
12. Stein CA, Cheng Y-C: Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 1993;261:1004-1012.
13. Helene C: Control of oncogene expression by antisense nucleic acids. Eur J Cancer 1994;30A:1721-1726.
14. Stein CA: Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: A question of mechanism. J Natl Cancer Inst 1996;88:391-393.
15. Perez JR, Li Y, Stein CA, et al.: Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 1994;91:5957-5961.
16. Engelhard HH, Narang C, Homer R, et al.: Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: In vitro and in vivo studies of uptake, effects and toxicity. Biochem Biophys Res Commun 1996;227:400-405.
17. Carter G, Lemoine NR: Antisense technology for cancer therapy: Does it make sense? Br J Cancer 1993:67:869-875.
18. Yazaki T, Ahmad S, Chahlavi A, et al.: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase. Mol Pharmacol 1996;50:236-242.
19. Wojcik WJ, Swoveland P, Zhang X, et al.: Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/ IP-10 in experimental allergic encephalomyelitis of Lewis rat. J Pharmacol Exp Ther 1996;278(1):404-410.
20. Wagner EGH, Simons RW: Antisense RNA control in bacteria, phages and plasmids. Annu Rev Microbiol 1994;48:713-742.
21. Redekop GJ, Naus CCG: Transfection with bFGF sense and antisense cDNA resulting in modification of malignant glioma growth. J Neurosurg 1995;82:83-90.
22. Cheng SY, Huang HJ, Nagane M, et al.: Suppression of glioblastoma and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996;93:8502-8507.
23. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cell in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996;56:393-401.
24. Shevelev A, Burfeind P, Schulze E, et al.: Potential triple helix-mediated inhibition of IGF-I gene expression significantly reduces tumorigenicity of glioblastoma in an animal model. Cancer Gene Ther 1997;4:105-112.
25. Ahmad S, Mineta T, Martuza RL, et al.: Antisense expression of protein kinase Ca inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 1994;35:904-909.
26. Go Y, Chintala SK, Mohanam S, et al.: Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin Exp Metastasis 1997;15:440-446.
27. Ashley DM, Kong FM, Bigner DD, et al.: Endogenous expression of transforming growth factor beta 1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 1998;58-302-309.
28. Prostko CR, Zhang C, Hait WH: The effects of altered cellular calmodulin expression on the growth and viability of C6 glioblastoma cells. Oncol Res 1997;9:13-17.
29. Sala A, Nicolaides NC, Engelhard A, et al.: Correlation between E2F-1 requirement in the S phase and E2F-1 transactivation of cell cycle-related genes in human cells. Cancer Res 1994;54:1402-1406.
30. Gewirtz AM, Stein CA, Glazer PM: Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc Natl Acad Sci USA 1996;93:3161-3163.
31. Wahlestedt C: Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol Sci 1994;15:42-46.
32. Agrawal S, Temsamani J, Galbraith W, et al.: Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995;28:7-16.
33. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993;268:14514-14522.
34. Egli M: Structural aspects of nucleic acid analogs and antisense oligonucleotides. Angew Chem Int Ed Engl 1996;35:1894-1909.
35. Miller PS: Antisense oligonucleoside methylphosphonates; in Mol JNM, van der Krol AR: Antisense Nucleic Acids Proteins. New York, Dekker, 1991, pp 241-253.
36. Murray JAH, Crockett N: Antisense Techniques: An overview. New York, Wiley-Liss, 1992.
37. Tonkinson JL, Stein CA: Antisense oligodeoxynucleotides as clinical therapeutic agents. Cancer Invest 1996;14:54-65.
38. Gryaznov SM, Lloyd DH, Chen J-K, et al.: Oligonucleotide N3′→P5′ phosphoramidates. Proc Natl Acad Sci USA 1995;92:5789-5802.
39. Tereshko V, Gryaznov S, Egli M: Consequences of replacing the DNA 3′-oxygen by an amino group: High-resolution crystal structure of a fully modified N3′-P5′ phosphoramidate DNA dodecamer duplex. J Am Chem Soc 1998;120:269-283.
40. Warzocha K, Wotowiec D: Antisense strategy: Biological utility and prospects in the treatment of hematological malignancies. Leuk Lymphoma 1997;24:267-281.
41. Cook PD: Medicinal chemistry strategies for antisense research; in Crooke ST, Lebleu B (eds): Antisense Research and Applications. Boca Raton, CRC Press, 1993, pp 149-187.
42. Manoharan M: Designer antisense oligonucleotides: Conjugation chemistry and functionality placement; in Crooke ST, Lebleu B (eds): Antisense Research and Applications. Boca Raton, CRC Press, 1993, pp 303-349.
43. Williams SA, Gillan ER, Knoppel E, et al.: Effects of phosphodiester and phosphorothioate antisense oligo-deoxynucleotides on cell lines which overexpress c-myc: Implications for the treatment of Burkitt's lymphoma. Ann Oncol 1997;8:25-30.
44. Leonetti JP, Machy P, Degols G, et al.: Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc Natl Acad Sci USA 1990;87:2448-2451.
45. Gokhale PC, Soldatenkov V, Wang FH, et al.: Antisense raf oligodeoxynucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: Implication for gene therapy of radioresistant cancer. Gene Ther 1997;4:1289-1299.
46. Cohen JS. Oligonucleotides as therapeutic agents. Pharmacol Ther 1991;52:211-225.
47. Cazenave C, Helene C: Antisense oligonucleotides; in Mol JNM, van der Krol AR: Antisense Nucleic Acids Proteins. New York, Dekker, 1991, pp47-93.
48. Askari FK, McDonnell WM: Molecular medicine: Antisense-oligonucleotide therapy. N Engl J Med 1996;334:316-318.
49. Crooke ST: Progress in antisense therapeutics. Med Res Rev 1996;16:319-344.
50. Baker BF, Lot SS, Condon TP, Cheng-Flourney S, Lesnik EA, Sasmor HM, Bennett CF: 2′-O-(2-methyoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level by formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997;272:11994-12000.
51. Heidenreich O, Gryaznov S, Nerenberg M: RNase H-independent antisense activity of oligonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res 1997;25:776-780.
52. Aggarwal BB, Schwarz L, Hogan ME, et al.: Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. Cancer Res 1996;56:5156-5164.
53. Eng LF: Current antisense nucleic acid strategies for manipulating neuronal and glial cells; in Antisense Nucleic Acid Technology. New York, Raven Press, 1993, pp 293-310.
54. Okada T, Yamaguchi K, Yamashita J: Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma. Growth Factors 1994;11:259-270.
55. Rininsland F, Johnson TR, Chernicky CL, et al.: Suppression of insulin-like growth factor type 1 receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA 1997;94:5854-5859.
56. Rossi JJ: Controlled, targeted, intracellular expression of ribozymes: Progress and problems. Trends Biotechnol 1995;13:301-306.
57. Fell PL, Hudson AJ, Reynolds MA, et al.: Cellular uptake properties of a 2′-amino/2′-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. Antisense Nucleic Acid Drug Dev 1997;7:319-326.
58. Agrawal S, Temsamani J, Tang JY: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 1991;88:7595-7599.
59. Saijo Y, Uchiyama B, Abe T, et al.: Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth in human lung cancer cells: Possible involvement of cell adhesion inhibition. Jpn J Cancer Res 1997;88:26-33.
60. Whitesell L, Geselowitz D, Chavany C, et al.: Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: Implications for therapeutic application within the central nervous system. Proc Natl Acad Sci USA 1993;90:4665-4669.
61. Morrison PF, Laske DW, Bobo H, et al.: High-flow microinfusion: Tissue penetration and pharmacodynamics. Am J Physiol 1994;266(1 Pt 2):R292-305.
62. Yee F, Ericson H, Reis DJ, Wahlestedt C: Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligodeoxynucleotides in the rat. Cell Mol Neurobiol 1994;14:475-486.
63. Ogawa S, Brown HE, Okano HJ, et al.: Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Regul Pept 1995;59:143-149.
64. Yaida Y, Nowak TS Jr: Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization. Regul Pept 1995;59:193-199.
65. Szklarczyk A, Kaczmarek L: Antisense oligodeoxyribonucleotides: Stability and distribution after intracerebral injection into rat brain. J Neurosci Methods 1995;60:181-187.
66. Broaddus WC, Prabhu SS, Gillies GT, et al.: Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion. J Neurosurg 1998;88:734-742.
67. Akhtar S, Agrawal S: In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 1997;18:12-18.
68. Baltuch GH, Dooley NP, Rostworowski KM, et al.: Protein kinase C isoform α overexpression in C6 glioma cells and its role in cell proliferation. J Neurooncol 1995;24:241-250.
69. Behl C, Winkler J, Bogdan U, et al.: Autocrine growth regulation in neuroectodermal tumors as detected with oligodeoxynucleotide antisense molecules. Neurosurgery 1993;33:679-685.
70. Engelhard HH, Rozental JM: Status of antisense oligodeoxynucleotides as a novel treatment for malignant glioma. Int J Oncol 1997;11(suppl):902.
71. Jachimczak PJ, Hessdorfer B, Fabel-Schulte K, et al.: Transforming growth factor-β-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligodeoxynucleotides. Int J Cancer 1996;65:332-337.
72. Mercer WE, Ullrich SJ, Shields MT, et al.: Cell cycle effects of microinjected antisense oligodeoxynucleotides to p34cdc2 kinase. Ann NY Acad Sci 1992;660:209-218.
73. Merzak A, Koocheckpour S, Pilkington GJ: CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res 1994;54:3988-3992.
74. Morrison RS: Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes. J Biol Chem 1991;266:728-734.
75. Murphy PR, Sato Y, Knee RS: Phosphorothioate antisense oligonucleotides against basic fibroblast growth factor inhibit anchorage-dependent and anchorage-independent growth of a malignant glioblastoma cell line. Mol Endocrinol 1992;6:877-884.
76. Nitta T, Sato K.: Specific inhibition of c-sis protein synthesis and cell proliferation with antisense oligodeoxynucleotides in human glioma cells. Neurosurgery 1994;34:309-315.
77. Resnicoff M, Sell C, Rubini M, et al.: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994;54:2218-2222.
78. Selinfreund RH, Barger SW, Welsh MJ, et al.: Antisense inhibition of glial S100β production results in alterations in cell morphology, cytoskeletal organization and cell proliferation. J Cell Biol 1990;111:2021-2028.
79. Van Eldik LJ, Barger SW, Welsh MJ: Antisense approaches to the function of glial cell proteins. Ann NY Acad Sci 1992;660:219-230.
80. Kondo S, Kondo Y, Hara H, et al.: Mdm2 gene mediates the expression of mdr1 gene snd P-glycoprotein in a human glioblastoma cell line. Br J Cancer 1996;74:1263-1268.
81. Chintala SK, Mohanam S, Go Y, et al.: Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor. Mol Carcinogen 1997;20:355-365.
82. Mohanam S, Chintala SK, Go Y, et al.: In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997;14:1351-1359.
83. Broaddus WC, Zhi JC, Prabhu SS, et al.: Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery 1997;41:908-915.
84. Liu J, Li H, Hamou MF: Inhibitory effect of antisense LIF oligonucleotide on the outgrowth of human medulloblastoma cells. Chinese J Pathol 1996;25:132-134.
85. Resnicoff M, Tjuvajev J, Rotman HL, et al.: Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA. J Exp Ther Oncol 1996;1:385-389.
86. Burgess TL, Fisher EF, Ross SL, et al.: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995;92:4051-4055.
87. Chavany C, Connell Y, Neckers L. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 1995;48:738-746.
88. Gura T: Antisense has growing pains. Science 1995;270:575-577.
89. Tidd DM: Anticancer drug design using modified antisense oligonucleotides; in Murray JAH (ed): Antisense RNA and DNA. New York, Wiley-Liss, 1992, pp 227-240.
90. Ma L, Calvo F: Recent status of the antisense oligonucleotide approaches in oncology. Fundam Clin Pharmacol 1996;10:97-115.
91. Rockwell P, O'Conner WJ, King K, et al.: Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 1997;94:6523-6528.
92. Hartmann G, Krug A, Eigler A, et al.: Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1996;6:291-299.
93. Ho PTC, Ishiguro K, Wickstrom E, et al.: Nonsequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides. Antisense Res Dev 1991;1:329-342.
94. Agrawal S, Zhang R: Pharmacokmetics of oligonucleotides. Ciba Found Symp 1997;209:60-75.
95. Pezeshki G, Schobitz B, Pohl T, Reul JM: Intracerebroventricular administration of missense oligodeoxynucleotide induces interleukin-6 mRNA expression in brain and spleen of rats. Neurosci Lett 1996;217(2-3):97-100.
96. Nagane M, Asai A, Shibui S, et al.: Application of antisense ribonucleic acid complementary to O6-methylguanine-deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas. Neurosurgery 1997;41:434-441.
97. Tortora G, Caputo R, Damiano V, et al.: Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci USA 1997;94:12586-12591.
98. Bayever E, Iversen P, Smith L, et al.: Guest Editorial: Systemic human antisense therapy begins. Antisense Res Dev 1992;2:109-110.
99. Bishop MR, Iversen PL, Bayever E, et al.: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies J Clin Oncol 1996;14:1320-1326.
100. Agrawal S, Jiang Z, Zhao Y, et al.: Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA 1997;94:2620-2625.